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Multiple factors determine the susceptibility to intrauterine hepatitis B virus (HBV) infection. These factors in-
clude the HBV structure, HBV mutation, HBV DNA level, placental barrier, the immune status of the mother, 
and the genetic make-ups of the newborn infants. Since HLA system is an integral component of the immune 
response, we hypothesized that the highly polymorphic HLA genes are the key determinants of intrauterine 
HBV infection. In this study, we selected newborn infants of HBsAg-positive mothers, and divided the infants 
into 2 groups: intrauterine infection group and non-intrauterine infection group according to the status whether 
or not they were infected at birth. Each infected infant was compared with 2 controls from the same birth cohort. 
HLA-DR allele typing was performed using a PCR-sequence specific primer (PCR-SSP) for 24 subjects with in-
trauterine infection and 48 controls without infection. We found that, among the fifteen (15) HLA-DR alleles as-
sessed, HLA-DRB1*07 was the one, and the only one, significantly in excess (OR = 6.66, P = 0.004) in the intrau-
terine infection group compared to the non-intrauterine infection group. Our findings thus suggest that high 
frequency of HLA class II molecules, e.g. HLA-DRB1*07, is associated with the susceptibility of the infants to 
intrauterine HBV infection. 
Key words: Hepatitis B virus (HBV); Human leukocyte antigen (HLA); Genetic susceptibility; Intrauterine infection; Nested 
case-control study 
1.  Introduction 
Hepatitis B is a common disease worldwide. Ap-
proximately, one million human deaths in the world 
each year are attributable to the end stage sequelae of 
persistent hepatitis B virus (HBV) infection. The 
World Health Organization (WHO) has estimated that 
about 350 million people worldwide are chronically 
infected with HBV [1]. These individuals are prone to 
the development of chronic hepatitis, liver cirrhosis, 
and hepatocellular carcinoma. In South East Asia, the 
mode of HBV infection is mainly vertical transmission 
in the perinatal period. In China, one of the major 
reasons for the high prevalence of HBV infection is 
that mothers transmit the HBV to their children dur-
ing the intrauterine as well as perinatal periods. Ap-
proximately 50% HBV carriers got infected via 
mother-to-infant transmission [1, 2, 3]. With the im-
munolization of hepatitis B vaccine and the use of 
hepatitis B immunoglobulin (HBIG) in hepatitis B 
surface antigen (HBsAg)-positive pregnant women, 
the incidence of HBV carrier status among the chil-
dren has reduced dramatically. However, intrauterine 
HBV infection still occurs at high incidence. The exact 
mechanisms underlying intrauterine infection of HBV 
have not been completely elucidated. Previous studies 
showed that major histocompatibility complex (MHC) 
gene products were vital for the regulation of several 
antiviral immune reactions [4, 5]. In addition, genetic 
factors controlling the host immune response could 
play an important role in determining the infection 
outcome [6, 7]. These immune responses may be ge-
netically determined, since studies on twins and fami-
lies have suggested the contribution of an inherited Int. J. Biol. Sci. 2008, 4 
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component in the development of chronic hepatitis B 
infection [8]. 
T cell responses are restricted by human leuko-
cyte antigen (HLA) class I and class II molecules, 
which present antigens to CD8+ cytolytic T cells and 
CD4+ helper T cells, respectively. The genes encoding 
HLA class I and class II molecules are the most poly-
morphic genes in the human genome and are there-
fore ideal candidates for the investigation of HBV in-
fection susceptibility. 
The association between HLA polymorphism 
and disease susceptibility as well as disease resistance 
has been documented [9, 10, 11]. Recently, several 
non-genetic diseases were found to be related to gene 
polymorphism, and the relationship between the 
TNF-α -238 A and IFN-γ +874 A alleles and intrauter-
ine HBV infection was reported [12, 13]. It is impor-
tant to further examine the relationship between in-
trauterine HBV infection and HLA gene polymor-
phism. 
To study the association between the polymor-
phisms of HLA class II genes and intrauterine HBV 
infection, we selected the newborn infants delivered 
by HBsAg-positive mothers in this study and com-
pared the frequencies of HLA phenotypes between the 
intrauterine HBV infection infant group and the 
non-intrauterine HBV infection infant group. To this 
end, an 1:2 matched nested case-control design was 
used.  
Materials and Methods 
Patients 
This study included the patients who visited the 
Department of Obstetrics and Gynecology at the Ma-
ternity and Child Care Centre of ShanXi Province 
from February 1999 to October 2004. A written con-
sent was obtained from each of the participants. A 
nested case-control design was used. The patients se-
lected were newborn infants whose blood were tested 
positive for HBsAg within 24 hr of birth (intrauterine 
HBV infection group, N = 24). The controls were 
newborn infants whose blood were tested negative for 
HBsAg (non-intrauterine HBV infection group, N = 
48). Each patient was compared with 2 controls from 
the same cohort based on factors that were associated 
with the pregnant women as well as the newborn in-
fants. These factors included age of the newborns 
(difference was within 6 months); same gender of the 
newborns, and the HBV marker levels in the maternal 
serum before delivery. 
Specimen Collection 
Venous blood specimens from pregnant women 
and femoral vein blood specimens of the newborn in-
fants were collected within 24 hr after birth and stored 
at –20°C for laboratory testing. After blood collection, 
the newborn infants immediately received hepatitis B 
immune globulin (HBIG) intramuscularly. They were 
also administered with hepatitis B vaccines at month 
0, 1, and 6. 
Criteria for Intrauterine HBV Infection 
Newborn infants whose venous blood specimens 
were collected within 24 hr after birth, if found posi-
tive for HBsAg and/or HBV DNA, were considered 
HBV infected intrauterinely. In order to exclude the 
possibility that the intrauterine infection was tested 
positive due to transplacental maternal contamination 
of the fetal circulation, we followed up all of the pa-
tients for at least 6 months. 
Determination of HBsAg and HBeAg in Serum 
The presence of serum HBsAg and HBeAg was 
tested by ELISA (Shanghai Ke-hua Biotechnology 
Company, Shanghai, China). The results were gener-
ated using a Multiskan MK3 ELISA detector. A posi-
tive/negative (P/N) ratio ≥ 2.1 was considered posi-
tive. 
Extraction of Genomic DNA 
The genomic DNA of the newborns was ex-
tracted from peripheral blood mononuclear cells by 
using the QIAamp blood kit (QIAGEN Inc., Chats-
worth, CA) according to the manufacturer’s instruc-
tions. 
HLA class II Typing 
HLA class II alleles were typed using the 
low-resolution DNA typing method––a polymerase 
chain reaction-sequence specific primer (PCR-SSP) 
technique (Pel-Freez, Brown Deer, WI) according to 
the manufacturer’s instructions. Gene typing was per-
formed using the software supplied by the company. 
Statistical analysis 
Statistical analysis was performed using the 
SPSS11.0 package software (SPSS Inc., Chicago, IL) on 
a computer. The frequency of HLA class II alleles was 
calculated by direct counting. Odds ratios (OR) reflect 
the likelihood of a specific allele being present in a 
subject who has intrauterine infection. P values were 
calculated by using conditional logistic regression. 
Statistic significance was tested by the chi-square test 
and Fisher’s exact test. P < 0.05 was considered statis-
tically significant. 
Results 
Patient characteristics 
A total of 312 HBsAg-positive pregnant women 
delivered 313 newborn infants from February 1999 to 
October 2004 in the Department of Obstetrics and 
Gynecology at the Maternity and Child Care Centre of Int. J. Biol. Sci. 2008, 4 
 
113
ShanXi Province. There were twins among these 
newborn infants. Among the 313 newborns, a total of 
24 fulfilled our criteria for intrauterine HBV infection, 
and the infection rate was 7.7% (24/313). There was a 
significant difference in the maternal serum HBeAg 
rate (χ2=19.50,  P<0.0001) and the newborn serum 
HBeAg rate (χ2=17.62, P<0.0001) between the intrau-
terine HBV infection and non-intrauterine HBV infec-
tion groups. These results indicate that maternal 
HBeAg-positive serum was a risk factor for intrauter-
ine HBV infection, and the OR was 5.95 (Table 1). In 
addition, newborn HBeAg-positive serum was also a 
risk factor with an OR of 5.39 (Table 1). 
Table 1 Relationship of serum HBeAg in mothers and newborns 
to intrauterine infection 
Maternal HBeAg  Newborn infants HBeAg  Group 
Positive 
(%) 
Negative 
(%) 
Total 
(n) 
Positive 
(%) 
Negative
(%) 
Total
(n) 
Intrauterine 
infection 
15(62.5%) 9(37.5%)  24    13(54.2%)  11(45.8%) 24 
Non-intrau-
terine in-
fection  
63(21.9%) 225(78.1%)  288   52(18.0%) 237(82.0%) 289 
Total 78(24.3%)  234(75.7%)  312    65(20.8%)  248(79.2%) 313 
χ2 19.50*      17.62* 
OR (95%CI)  5.95 (2.29-16.8)    5.39 (2.08-13.99) 
*P < 0.0001 
 
There was no statistically significant difference (P 
> 0.05) between the infected infants and controls with 
respect to the mean age and occupation of the moth-
ers, nor the birth weight and gender of the newborn 
infants. 
Distribution of HLA-DR type in the intrauterine 
infection and non-intrauterine infection groups 
In all the newborn infants, DRB3* was the most 
frequent HLA-DR type. Its frequency was 37.5% in the 
intrauterine infection group and 29.17% in the 
non-intrauterine infection group (Table 2). In the in-
trauterine infection group, DRB1*07 and DRB3* were 
the most frequent HLA-DR type (both were 37.5%) in 
newborn infants, followed by DRB1*08 (20.83%). In 
the non-intrauterine infection group, DRB3* was the 
most frequent HLA-DR type (29.17%), followed by 
DRB1*12 (18.75%) (Table 2). 
Comparison of the frequency of the HLA-DR type 
between the intrauterine infection and 
non-intrauterine infection groups 
There was a significant difference in the distribu-
tion of HLA-DRB1*07 between the intrauterine infec-
tion and non-intrauterine infection groups. 
HLA-DRB1*07 was significantly more frequent in the 
intrauterine infection group (9 of 24 subjects, 37.5%) as 
compared to its frequency in the non-intrauterine in-
fection group (4 of 48 subjects, 8.33%) (OR = 6.66, P = 
0.004) (Table 3). The same analysis did not yield evi-
dence supporting the significant (p<0.05) involvement 
of other HLA-DR types as determinants of intrauter-
ine infection (Table 3). 
Table 2 Frequencies of HLA-DR types in the intrauterine in-
fection and non-intrauterine infection groups# 
Intrauterine infection 
group (N=24) 
 Non-intrauterine  infection 
group 
(N=48) 
HLA-DR 
Allele type 
N %    n  % 
DRB1*01 2  8.33   2  4.17 
DRB1*03 2  8.33   5  10.42 
DRB1*04 4  16.67   3  6.25 
DRB1*07 9  37.5   4  8.33 
DRB1*08 5  20.83   5  10.42 
DRB1*09 4  16.67   4  8.33 
DRB1*10 3  12.5   2  4.17 
DRB1*11 3  12.5   7  14.58 
DRB1*12 2  8.33   9  18.75 
DRB1*14 1  4.17   7  14.58 
DRB1*15 1  4.17   8  16.67 
DRB1*16 2  8.33   3  6.25 
DRB3* 9  37.5    14  29.17 
DRB4* 4  16.67    5  10.42 
DRB5* 1  4.17    3  6.25 
#The allele carrier frequencies are referred to the frequencies of the 
population, not individuals. 
Table 3 Comparison of HLA-DR types between the intrauterine 
infection and non-intrauterine infection groups 
Frequency(%)in  
Subjects with 
HLA-DR 
allele 
Intrauterine 
infection 
(n=24) 
Non-intrauterine 
infection (n=48) 
OR 95%CI  P 
DRB1*01 8.33 4.17  2.091  0.276-15.83 0.597
DRB1*03 8.33 10.42  0.782  0.14-4.36  0.571
DRB1*04 16.67 6.25  3.00  0.61-14.67 0.212
DRB1*07 37.5 8.33  6.66  1.77-24.59 0.004
DRB1*08 20.83 10.42  2.26  0.58-8.74  0.285
DRB1*09 16.67 8.33  2.2  0.49-9.69  0.427
DRB1*10 12.5 4.17  3.28  0.51-21.15 0.325
DRB1*11 12.5 14.58  0.83  0.19-3.57  0.81 
DRB1*12 8.33 18.75  0.39  0.08-1.98  0.32 
DRB1*14 4.17 14.58  0.25  0.29-2.20  0.25 
DRB1*15 4.17 16.67  0.21  0.03-1.85  0.26 
DRB1*16 8.33 6.25  1.36  0.21-8.76  1.00 
DRB3* 37.5  29.17  1.45  0.52-4.10  0.59 
DRB4* 16.67  10.42  1.72  0.42-7.10  0.47 
DRB5* 4.17  6.25  0.65  0.06-6.62  1.00 
Discussion 
The susceptibility of HBV infection and the im-
mune response to HBsAg-derived vaccines are deter-
mined by the genetic background of the host [14, 15]. 
Other outcomes, including progression to cirrhosis 
and/or liver cancer, may also be influenced by host 
genetics. Thus far, the results of studies on host sus-
ceptibility to HBV infection are not conclusive. From 
the viewpoint of epidemiology, the major problem is 
the lack of appropriate subjects and suitable research Int. J. Biol. Sci. 2008, 4 
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design. In general, in order to conduct such studies, all 
subjects should be exposed to HBV. In addition, the 
time and mode of exposure to HBV should be compa-
rable. Then, the difference in the distribu-
tion/frequencies of HLA types can be compared be-
tween HBV-infected persons and non-infected con-
trols. Unfortunately, such study designs can hardly be 
realized if our epidemiological survey is based on the 
common human population. This is because: (1) It is 
difficult to determine the precise time of HBV expo-
sure and to conduct follow-ups in common human 
population; (2) Theoretically, we would first require 
an isolated population from which our subjects can be 
selected. From this isolated population, the susceptible 
population should be screened, and subsequently, the 
infection status of this population should be followed 
up. However, this is extremely difficult to achieve. 
Fortunately, intrauterine HBV infection can be studied 
in newborn infants who are suitable study subjects. 
Because the newborn infants we studied were all de-
livered by HBsAg-positive mothers, they were all 
susceptible to HBV, and their mothers were the only 
source of HBV infection. These conditions well satis-
fies our research design requirements. 
HLA is involved in immune response to HBV. 
Although the relationship between various clinical 
manifestations and polymorphic HLA genes have 
been the subject of several studies, a definitive rela-
tionship has not yet been identified due to the incon-
sistencies of the results [4, 16, 17, 18]. While the 
mechanism of susceptibility to HBV infection is not 
well clarified, it is known to be influenced by host 
immunogenetic factors [19, 20].   
Our results show that maternal HBeAg-positive 
serum and newborn HBeAg-positive serum were risk 
factors for intrauterine HBV infection. Several reports 
indicated that the likelihood of developing chronic 
HBV infection is higher in newborn infants, whose 
immune systems are thought to be immature, com-
pared with the immunocompetent subjects during 
adulthood [14, 23]. The natural course of chronic HBV 
infection can be divided into four phases based on the 
virus-host interaction: immune tolerance, immune 
clearance, low or non-replication, and reactivation. 
Most carries with intrauterine HBV infection are pre-
sent in the immunotolerant phase. These carries are 
HBeAg positive but with normal alanine aminotrans-
ferase (ALT). 
Our study has indicated that 
HLA-DRB1*07(HLA-DR7) type is associated with 
HBV intrauterine infection in Chinese people. It is no-
ticeable that in this study the newborn infants with 
non-intrauterine HBV infection were selected as the 
controls, which ensured a similar exposure to HBV 
between the case and control groups. Our results im-
ply that susceptibility to persistent infection is signifi-
cantly associated with the presence of HLA-DR7 type. 
Almarri et al [21] failed to identify an association be-
tween HLA class I and chronic HBV infection. How-
ever, they discovered a significant decrease in the 
frequency of HLA-DR2 and an excess of HLA-DR7 in 
cases of chronic, persistent HBV infection. 
HLA-DRB1*1301/2 has been associated with viral 
clearance, but HLA-DRB1*07(HLA-DR7) is associated 
with non-responsiveness to vaccination with envelope 
proteins [4, 22]. It is possible that high expression of 
HLA-DR7 on the cell surface may restrict the ability of 
helper T-lymphocytes to recognize HBsAg and B-cells 
and thereby result in persistent infection. Alterna-
tively, HLA-DR7 may present viral peptides to a spe-
cific subset of CD4+ T cells and therefore alt the sub-
sequent immune responses. Nevertheless, compared 
with our study, those studies did not show the role of 
HLA-DRB1*07(HLA-DR7) in HBV intrauterine infec-
tion.  
To the best of our knowledge, this is the first re-
port involving the study on the association between 
HLA phenotypes and the outcomes of intrauterine 
HBV infection in newborn infants. Our data have 
showed that high frequency of specific HLA pheno-
types, such as DRB1*07, is associated with the suscep-
tibility to HBV intrauterine infection. Thus, our find-
ings support the conclusion that genetic factors (e.g., 
HLA) are associated with the outcomes of intrauterine 
HBV infection. The characterization of functional sig-
nificance of this particular HLA molecule in HBV in-
trauterine infection may provide insight to develop 
novel prophylactic and therapeutic approaches. Addi-
tional study is needed to validate these findings and to 
further explore the relationship between HBV intrau-
terine infection and the susceptible gene(s), as well as 
any other risk factors which may be involved in HBV 
intrauterine infection. Finally, investigation to eluci-
date the genetic pathogenesis of HBV intrauterine in-
fection is among the future studies we plan to pursue.   
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